Off-label prescribing of antidepressants and anxiolytics: An attorney's guide to psychoactive drugs

Journal of Psychiatry and Law

Volumn 26, Issue 4, 1998, Pages 519-532

  Kuntz, Richard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORDIAZEPOXIDE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; DISULFIRAM; DOXEPIN; ESTAZOLAM; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE MALEATE; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; NALTREXONE; NEFAZODONE; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; QUAZEPAM; SERTRALINE; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; VENLAFAXINE; ZOPICLONE;

ALCOHOLISM; DEPRESSION; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; INSOMNIA; PHYSICIAN; PRESCRIPTION; REVIEW;

EID: 0032418436     PISSN: 00931853     EISSN: None     Source Type: Journal    
DOI: 10.1177/009318539802600404     Document Type: Review

References (46)

1. See, e.g., Beck, JM & Azari, ED, FDA, off-label use, and informed consent, 53 Food and Drug Law J., 71, 76-80 (1998).
2. Janik et al., Principles and Practice of Psychopharmacology at 56 (2d ed. 1997).
3. Public Law 105-115.
4. 63 Fed. Reg. 31143-31161 (June 8, 1998). The rules took effect on November 21, 1998. That FDA approval may not readily be granted under this authority can be gleaned from the FDA's rejection of numerous health and nutritional claims from supplement manufacturers under existing statutory authority granted in Sections 303 and 304 of the same Modernization Act amendments.
5. See, e.g., 63 Fed. Reg. 34107 (June 22, 1998) (rejecting claims that omega-3 fatty acids reduce the risk of cardiovascular disease).
6. 21 U.S.C. 321 et seq.
7. Jefferson, Drug and diet interactions: avoiding therapeutic paralysis, 59 J. Clin. Psychiatry (Supp. 16), 31-39 (1998).
8. Hartman, Neuropsychological Toxicity at 274 on (2d ed. 1995).
9. Depulta and Pomara, Effects of antidepressants on human performance: A review, 10 J. of Clinical Psychopharmacology, 105-111 (1990).
10. Daly, Medico-legal aspects of prescribing, 9 Human Psychopharmacology, 35-36 (1994).
11. No. 3-97-0680 (Ill. App. Sept. 24, 1998).
12. No. 84667 (Ill. S. Ct. Dec. 17, 1998), reversing 292 Ill. App. 3d 580, 686 N.E. 2d 617 (1997).
13. See Dunner & Kulman, Paroxetine, a review of clinical experience, 31 Pharmacopsychiatry 89-101 (May 1998).
14. Highly selective SSRI approved by FDA for depression, 26 Clinical Psychiatry News 9:1, 6-7 (October 1998).
15. Thase, ME, Depression, sleep and antidepressants. 59 J. of Clin. Psychiatry (Supp. 4), 62 (1998).
16. Yamadera, Effects of trazodone hydrochloride and imipramine on polysomography in healthy subjects, 52 Psychiatry and Clinical Neuroscience, 435-443 (1998).
17. Sharf, MB and Sachais, BA, Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients, 51 J. Clin. Psychiatry, 13-17 (1990).
18. Ware, JC and Pittard, JT, Increased deep sleep after trazodone use: A double-blind placebo-controlled study in healthy young adults, 51 J. Clin. Psychiatry, 18-22 (1990).
19. Okino, H, Sugawara, K, Yagasaki, N et al., Effects of trazodone on nocturnal sleep, 6 Psychosom. Ther., 61-89 (1994) (in Japanese).
20. Montgomery, I, Oswald, I, Morgan, K, Adam, K, Trazodone enhances sleep in subjective quality but in objective duration, 16 Br. J. Clin. Pharmacol., 139-144 (1983).
21. Walsh, JK et al., Subjective hypnotic efficacy of trazodone and zolpidem in DSM III-R primary insomnia, 13 Human Psychopharmacology, 191-198 (June 1998).
22. Sennef, C et al., Effects of mirtazapine, amitriptyline, and their combination on sleep in healthy volunteers. Poster presentation, Organon, NV, 1998.
23. In some states, notably New York, benzodiazepine prescribing is subject to rigorous regulation, including a requirement for triplicate copies of prescriptions. Paradoxically this has led to an increased utilization of the older hypnotics, which are not regulated in this fashion.
24. Schweizer and Rickels, Benzodiazepine dependence and withdrawal: A review of the syndrome and its clinical management, 98 Acta Psychiatrica Scandinavia (Supp. 393), 95 (1998).
25. Rush, CR et al., Benzodiazepine recepter ligands in humans: Acute performance-impairment and subject-rated effects, 18 Journal of Clinical Psychopharmacology, 154-166 (April 1998).
26. Hunt, TL et al., Comparison of 24-h plasma concentrations of the N-desalkyl metabolite of quazepam and flurazepam in a single-dose study, 3 J. Pharm. Med., 3-9 (1993).
27. Kupfer and Reynolds, Current concepts: Management of insomnia, 336 New England J. of Med., 341, 343 (Jan. 30, 1997).
28. Rush, Behavioral pharmacology of zolpidem relative to benzodiazepines: A review, 61 Pharmacol. Biochem. Behav., 253-269 (Nov. 1998).
29. Sakamole, K et al., Efficiency of L-846 in patients with insomnia: Evaluation by poly-somnography, 52 Psychiatry and Clinical Neuroscience, 156-157 (1998).
30. Hajak, Doxepin Improves Sleep in Primary Insomnia (in press).
31. Hohgen, F et al., Trimipramine, an alternative to benzodiazepines in primary insomnia, 244 European Archives of Psychiatry and Clinical Neuroscience, 65-72 (1994). No generic equivalent for trimipramine is approved in the U.S.
32. Verman, NP et al., Nefazodone is effective in the treatment of insomnia [abstract], 21 Sleep 302 (Supp. 1998).
33. 880 F. Supp. 26, 28 n.1 (D.D.C. 1998).
34. 93 F. 3d 511, 514 n.3 (8th Cir. 1996).
35. 298 So. 2d 149, 153 (La. App. 1974).
36. 55 Ill. 2d 411 (1973).
37. 288 Minn. 232 (1970).
38. 118 Ill. 2d 321 (1987).
39. 124 Ill. App. 3d 42 (1984).
40. 255 Ill. App. 3d 233 (1993).
41. See, e.g., the text cited supra, n.1 and references therein, the articles cited in this review, and American Psychiatric Association, Textbook of Psychopharmacology (2d ed. 1998).
42. 275 Ill. App. 3d 593, 656 N.E. 2d 23, 32 (1995).
43. 291 Ill. App. 3d 265, 682 N.E. 2d 1203 (1997).
44. 34 Psychopharmacology Bulletin, 111-115 (1998).
45. 31 Pharmacopsychiatry, 110-113 (1998).
46. 280 Journal of the American Medical Association, 1363 (October 21, 1998).